Fosun International LTD Cyma Bay Therapeutics, Inc. Transaction History

Fosun International LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$3.22 - $6.27 $595,700 - $1.16 Million	-185,000 Reduced 70.2%	78,529 $492,000
Q2 2020 Aug 12, 2020	SELL	$1.41 - $4.25 $520,089 - $1.57 Million	-368,858 Reduced 58.33%	263,529 $920,000
Q1 2020 May 11, 2020	SELL	$1.25 - $2.02 $169,693 - $274,225	-135,755 Reduced 17.67%	632,387 $936,000
Q3 2019 Nov 12, 2019	SELL	$5.12 - $7.21 $337,684 - $475,528	-65,954 Reduced 7.91%	768,142 $3.93 Million
Q2 2019 Aug 12, 2019	BUY	$6.05 - $13.66 $254,100 - $573,720	42,000 Added 5.3%	834,096 $5.94 Million
Q4 2018 Jan 31, 2019	BUY	$6.54 - $11.74 $2.15 Million - $3.85 Million	328,289 Added 70.78%	792,096 $6.2 Million
Q3 2018 Nov 09, 2018	BUY	$10.88 - $14.52 $5.05 Million - $6.73 Million	463,807 New	463,807 $5.15 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Fosun International LTD, based on Form 13F filings with the SEC.

Stay updated on Fosun International LTD with notifications on news.